Non-small cell lung cancerSquamous cell carcinomaAdenocarcinomaSublobectomyOncologic outcomeRecent studies recommend sublobectomy as a surgical approach for non-small cell lung cancer (NSCLC) tumors that are 2cm or smaller. However, it remains unclear whether NSCLC patients with squamous cell carcinoma (...
3.1.1 Lung squamous cell carcinoma Lung squamous cell carcinoma (LUSC) belongs to the class of non-small cell lung carcinomas (NSCLC) that account for ca. 85% of all lung cancers. It is strongly associated with smoking and it is among cancers with the highest mutation frequency ...
SQUAMOUS cell carcinomaLUNG cancer diagnosisGIANT cell tumorsHISTOPATHOLOGYBRONCHOSCOPYStromal reactions including benign osteoclast-like giant cells are rarely seen within carcinomas. They are even extremely rare in lung carcinomas. A 61-year-old male patient who had marked volume los...
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As...
Matthew Meyerson, Ramaswamy Govindan and colleagues examine the exome sequences and copy number profiles of 660 lung adenocarcinoma and 484 lung squamous cell carcinoma tumors. They identify novel significantly mutated genes and amplification peaks and f
NSCLC patients included 23 squamous cell carcinomas (SCCs), 101 adenocarcinomas (ADCs) and 1 large cell carcinoma. The expression level of microRNA-141 was significantly higher in NSCLC tissues than in adjacent lung tissues (P < 0.001), detected by real time RT-PCR. Receiver operating ...
a pattern of central necrosis in small islands of tumor cells may create a pseudoglandular appearance that can be confused with adenocarcinoma. In addition, some squamous cell carcinomas of the lung may resembleangiosarcomahistologically because of the formation of anastomosing spaces that are ...
Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer wild-type p53 (35.7% vs 53.8%; P=0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma... CL Huang,T Taki,M Adachi,.....
Chemo-activation of mitochondrial ClpP exhibits promising anticancer properties. However, we are currently unaware of any studies using selective and potent ClpP activators in lung squamous cell carcinoma. In this work, we report on such an activator, ZK
Lung cancer is the main cause of cancer death worldwide, with lung squamous cell carcinoma (LUSC) being the second most frequent subtype. Preclinical LUSC models recapitulating human disease pathogenesis are key for the development of early intervention